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ABSTRACT 1 
Objective 2 
This paper aims to provide an overview of the added societal value of generic medicines beyond their 3 
cost-savings potential through reduced prices. In addition, an observational case study will document 4 
the impact of generic entry on access to pharmacotherapy in the Netherlands and an illustrative 5 
exercise was carried out to illustrate the budget impact of generic entry 6 
Methods 7 
A narrative literature review was carried out to explore the impact of generic medicines on access to 8 
pharmacotherapy, innovation and medication adherence. Data from the Medicines and Medical 9 
Devices Information Project database in the Netherlands were used for the case study in which the 10 
impact of entrance of generic medicines on the budget and the number of users was calculated as an 11 
illustrative exercise. 12 
Results 13 
Generic medicines have an additional societal value beyond their cost-savings potential through 14 
reduced prices. Generic medicines increase access to pharmacotherapy, provide a stimulus for 15 
innovation by both originator companies and generic companies and, under the right circumstances, 16 
have a positive impact on medication adherence. 17 
Conclusion 18 
Generic medicines offer more to society than only their cost-savings potential trough reduced prices. 19 
As such, governments must not only focus on the prices of generic medicines as this will threaten their 20 
long-term sustainability. Governments must therefore act appropriately and implement a coherent set 21 
of policies to increase the use of generic medicines.  22 
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Key issues 1 
• Generic medicines have contributed considerably to contain escalating health care budgets in 2 
the past but contribute more to society than only their cost-savings potential through reduced 3 
prices. 4 
• The reduced prices of generic medicines improve the cost-effectiveness of existing 5 
pharmacotherapy, make it cost-effective to manage previously untreated patients or lead to a 6 
more optimal treatment of some diseases. 7 
• Generic medicines can have a positive impact on medication adherence but only under the 8 
right circumstances 9 
• The entrance of generic medicines provides a stimulus for originator companies to invest in 10 
innovation 11 
• Generic medicines companies are stimulated to innovate in order to differentiate themselves 12 
in the highly competitive market 13 
• To maximize  the benefits of generic medicines in the long-term, governments must act 14 
judiciously to implement a coherent set of policies to increase the use of generic medicines 15 
instead of continuously putting pressure on the prices 16 
  17 
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INTRODUCTION 1 
In current times of financial and economic hardship, many European governments have 2 
accommodated generic medicines as a means to contain increasing pharmaceutical expenditures [1]. 3 
Generic medicines are substitutes for originator medicines with the same quality, safety, and efficacy 4 
and whose bioequivalence has been demonstrated by appropriate bioavailability studies [2]. Generic 5 
medicines offer equally high-quality treatment at lower costs, as prices of generic medicines in Europe 6 
tend to be 20-80% lower than those of their originator equivalent counterparts [3-5], although these 7 
can be as low as 2-4% of the prices before patent expiry in some countries [6-9]. Many European 8 
governments have therefore adopted policies to increase the use of generic medicines, which can be 9 
situated at both the supply-side (i.e. policies related to market access, pricing and reimbursement of 10 
generic medicines) and the demand-side (i.e. incentives for physicians, pharmacists and patients to 11 
prescribe, dispense or ask for generic medicines) [1;10;11]. Several countries have achieved 12 
substantial savings on their pharmaceutical expenditures through generic medicines, as extensively 13 
documented in the literature [6-9;12-17]. However, a viable and sustainable generic medicines 14 
industry contributes more to society than only an opportunity to contain pharmaceutical expenditures 15 
through reduced prices. From a health perspective, generic medicines might also have an important 16 
impact on access to pharmacotherapy, innovation and potentially also to medication adherence.  17 
This paper aims to provide an overview of the added societal value of generic medicines, other than 18 
their potential for cost-savings through reduced prices. To this effect, a narrative literature review has 19 
been carried out to explore the impact of generic medicines on access to pharmacotherapy, innovation 20 
and medication adherence. In addition, an observational case study was used to describe the impact 21 
of generic entry on access to pharmacotherapy in the Netherlands and an illustrative exercise was 22 
carried out to depict the impact of generic entry on both the budget and the number of users in the 23 
Netherlands. 24 
METHODOLOGY 25 
Literature review 26 
A narrative literature review was carried out to explore the impact of generic medicines on access to 27 
pharmacotherapy, innovation and medication adherence. The following databases were searched: 28 
Pubmed and Embase. The search strategy was developed using combinations of different terms 29 
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relevant to the subject. The following search terms were used: generic medicines; generic drugs; 1 
generics; adherence; patient adherence; compliance; generic substitution; innovation; innovativeness; 2 
patient access; access; pharmacotherapy; and therapy.  3 
Studies could be published in English, French or Dutch. Additional articles were identified by a review 4 
of the reference lists of articles and articles known to the authors. 5 
Case study 6 
Data source 7 
Data were derived from the Medicines and Medical Devices Information Project (GIP) database in the 8 
Netherlands. The National Health Care Institute  systematically collects data on the developments of 9 
the use of medicines and medical devices in outpatient care in their GIP database. Data are collected 10 
from 23 Health Insurance Companies, who had a nationwide coverage of around 97% in 2012. The 11 
data from the Health Insurance Companies are subsequently incremented by the GIP to obtain a 12 
nationwide picture, thereby taking into account the differences in age structure and gender between 13 
the different Health Insurance Companies and their market share. 14 
The variables delivered in the extracted dataset were the name of the active substance, the 15 
Anatomical Therapeutic Chemical (ATC)-code, the counting defined daily doses (DDD, index 2013 16 
[18]), the total costs and the total number of users, each time split up between the originator medicine 17 
and the generic versions. The concept of DDD is used because it enhances the comparability between 18 
different drugs and drug classes, especially where there are differences in pack sizes and available 19 
tablet strengths [19;20] 20 
Selection of medicines 21 
A total of 14 active substances were selected for the analysis (see Table 1). The active substances 22 
were selected so that different therapeutic areas were covered and that the generic versions of the 23 
active substances entered the market between 2002 and 2012 in order to have data of at least two 24 
years before and after the generic entry. The selected medicines were omeprazol (A02BC01), 25 
pantoprazol (A02BC02), esomeprazol (A02BC05), clopidogrel (B01AC04), amlodipine (C08CA01), 26 
felodipine (C08CA02), lisinopril (C09AA03), perindopril (C09AA05), ramipril (C09AA05), quinapril 27 
(C09AA06), simvastatin (C10AA01), fluvastatin (C10AA04), temozolomide (L01AX03) and alendronic 28 
Acid (M05BA04). 29 
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Calculation of budget impact 1 
An illustrative exercise was carried out to calculate the budget impact if no generic versions of the 14 2 
selected active substances would have entered the market. For this exercise, it was assumed that the 3 
number of counting DDD would have evolved in the same way as it has actually evolved with the entry 4 
of generic medicines. Four different scenarios of potential budget impact were calculated: one in which 5 
the cost/DDD of the originator medicine would remain at the level of the year prior to generic entry; 6 
one in which the cost/DDD of the originator medicine would be 25% lower; one in which the cost/DDD 7 
of the originator medicine would be 50% lower; and one where the cost/DDD of the originator medicine 8 
at the year of generic entry would be at the level of the cost/DDD of the originator medicine in 2013. 9 
For each selected active substance, the cost/DDD of the originator medicine was calculated by 10 
dividing totals costs by the number of counting DDDs in the year before generic entry. This cost/DDD 11 
of the originator medicine was then multiplied by the number of counting DDD for each year. The 12 
cumulative budget impact was then estimated by calculating the difference between the calculated 13 
total costs and the actual costs and this for the entire period between generic entry and 2013. 14 
Calculation of impact on number of users 15 
AN ILLUSTRATIVE EXERCISE WAS CARRIED OUT TO CALCULATE THE IMPACT ON THE NUMBER OF USERS IF NO 16 
GENERIC VERSIONS OF THE 14 SELECTED ACTIVE SUBSTANCES WOULD HAVE ENTERED THE MARKET. FOR 17 
THIS EXERCISE, IT WAS ASSUMED THAT THE TOTAL COSTS (I.E. BUDGET) WOULD HAVE EVOLVED IN THE SAME 18 
WAY AS THEY HAVE ACTUALLY EVOLVED WITH THE ENTRY OF GENERIC MEDICINES. THE AVERAGE COST PER 19 
USER FOR THE ORIGINATOR MEDICINE WAS CALCULATED IN THE YEAR PRIOR TO GENERIC (I.E. DIVIDING TOTAL 20 
COSTS BY TOTAL USERS). ASSUMING THAT THE AVERAGE COST PER USER WOULD HAVE REMAINED 21 
CONSTANT, THE NUMBER OF USERS THAT COULD HAVE BEEN ACCOMMODATED WITH THE BUDGET OF 2013 22 
WAS SUBSEQUENTLY CALCULATED (I.E. DIVIDING TOTAL COSTS IN 2013 BY AVERAGE COST/USER OF YEAR 23 
PRIOR TO GENERIC ENTRY).RESULTS 24 
Impact on access to pharmacotherapy 25 
Generic medicines play an essential role in treating diseases. They do not only increase the 26 
affordability of modern day pharmaceuticals, their reduced prices also increase access to 27 
pharmacotherapy [21]. For instance, a recent study, which analyzed the availability of essential 28 
medicines around the globe, highlighted the important contribution of generic medicines to an 29 
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increased availability of essential medicines. Worldwide, essential medicines were found to be more 1 
available than non-essential medicines. The median availability of essential medicines was 61.5%, of 2 
which a substantial contribution was made by generic medicines (53.3%) [22]. Since 2001, the 3 
average price of treatment for seven therapeutic areas in Europe where generic medicines are 4 
available has declined over 60% whilst the number of treatment days where a generic medicine is 5 
used has increased over 200%. In the end, the total cost of treatment for governments remained even 6 
but substantially more patients were treated In 2013, for instance, of the 82 million patients receiving 7 
hypertension treatment in the EU, 48 million of them were treated by a generic medicine (i.e. 59%) 8 
[23].  9 
The availability of generic medicines is also likely to increase access to pharmacotherapy for certain 10 
medicines of which the reduced prices of generic medicines are expected to improve the cost-11 
effectiveness of existing pharmacotherapy, thereby introducing these medicines earlier in the 12 
treatment algorithm. This was the case for atorvastatin, for instance, of which generic equivalents 13 
entered the market in European member states in 2012. A literature review, which examined the cost-14 
effectiveness of atorvastatin in cardiovascular diseases, demonstrated that generic atorvastatin is 15 
cost-effective as compared to simvastatin for a number of indications (i.e. in primary and secondary 16 
prevention of cardiovascular disease, in secondary prevention of coronary heart disease, in patients at 17 
low cardiovascular risk, and in patients with acute coronary syndrome). The cost-effectiveness of 18 
generic atorvastatin is influenced by the price difference between branded and generic atorvastatin,  19 
on whether the comparator is a generic or branded statin, and on the size of the required reduction in 20 
low-density lipoprotein cholesterol level [24]. 21 
In addition to improving the cost-effectiveness of existing pharmacotherapy, the entry of generic 22 
medicines may also make it cost-effective to manage previously untreated patients. The entry of 23 
lower-priced generic medicines, for instance, would make statin therapy cost-effective for a wider 24 
range of individuals with annual risks of major vascular events well below those previously recognized 25 
in the clinical treatment guidelines [25;26]. 26 
The entry of generic medicines at lower prices might also lead to a more optimal treatment of some 27 
diseases. For instance, there is evidence in the literature that ductal closure of preterm infants benefits 28 
from a higher dose of the orphan medicine ibuprofen administrated earlier in life. At this moment, 29 
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physicians hesitate to prescribe this higher dose as a result of the high price of the non-generic orphan 1 
medication [27]. 2 
Impact on innovation 3 
Innovation is essential for the generic medicines industry, as today’s innovative medicines give rise to 4 
tomorrow’s generic medicines and all generic medicines can trace their origins back to originator 5 
medicines [28]. A robust generic medicines market is generally understood to have a positive impact 6 
on innovation in the pharmaceutical sector [28]. Entry of generic medicines generates competition, 7 
which is essential for inducing innovation by originator companies [21;29]. This competition is usually 8 
accompanied by a reduction of prices of medicines and a reduction of the market shares of originator 9 
medicine. As such, originator companies’ turn-over on the respective originator medicines decreases 10 
substantially, which provides a stimulus for originator companies to bring new, (innovative) medicines 11 
to the market in order to sustain their business model [30]. In turn, savings on the pharmaceutical 12 
budget generated by generic medicines can be used to accommodate the introduction of innovative, 13 
more expensive medicines whilst containing costs [21;28]. 14 
Generic medicines do not only provide a stimulus for originator companies to innovate, they also 15 
encourage generic companies to innovate in order to differentiate themselves in this highly competitive 16 
market, for instance by addressing on patients’ and pharmacists’ needs [21;31]. These companies try 17 
to create a market advantage through creating another type of ‘added value’.  This type of 18 
innovativeness by generic companies becomes evident in, for instance, packaging specifically 19 
designed to help patients and minimise pharmacy dispensing errors, packaging to reduce wasting, 20 
smart packaging to support medication adherence, production of combinations of routinely co-21 
prescribed off-patent medicines to aid patient compliance, development of novel drug delivery 22 
systems, development of devices to facilitate administration of medicines, etc. This topic is, however, 23 
poorly documented in the literature but confirmed by practicing hospital pharmacists. 24 
Impact on medication adherence 25 
By concentrating on patients’ and pharmacists’ needs, the different types of innovativeness of generic 26 
medicines might have a positive impact on medication adherence. However, the reduced prices of 27 
generic medicines might also have their impact on medication adherence. High out-of-pocket costs for 28 
medicines is one of the best documented barriers to medication adherence [32]. Previous research 29 
has shown that increased co-payments are associated with a decrease of both first-fill adherence [33] 30 
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and re-fill adherence of medicines [34-44]. As such, a reduction of co-payments has a positive effect 1 
on medication adherence. 2 
Generic medicines, which generally benefit from lower prices and co-payments than their originator 3 
equivalents, might subsequently have a positive impact on medication adherence [44-53]. In the 4 
United States, where 3-tiered plans are instituted, generic medicines generally have the lowest co-5 
payment, followed by preferred branded medicines and non-preferred branded medicines which have 6 
the highest co-payment. Both Shrank et al. and Briesacher et al. showed that initiation of therapy with 7 
generic medicines vs. preferred medicines or non-preferred medicines increased medication 8 
adherence [45;46]. Two case studies by Simoens et al. in a Belgian hospital setting demonstrated an 9 
improved patient medication adherence to statin therapy following a switch to generic statins [44]. Also 10 
in Italy, where a reference pricing system applies to off-patent medicines, an increased medication 11 
adherence for patients treated with generic medicines vs. off-patent originator medicines was 12 
observed after 34 months of observation [47]. In the Netherlands, generic substitution of 13 
antihypertensive drugs did not lead to lower medication adherence between 1999 and 2002. Instead, 14 
medication adherence increased from 81.3% for patients who stayed on the originator medicine to 15 
86.4% for patientswho switched to generic medicines [48]. Nevertheless, the Netherlands might be a 16 
special case as there is no co-payment on medicines. 17 
However, generic medicines might also have a negative effect on medication adherence, especially in 18 
relation to generic substitution. Generic substitution allows pharmacists to dispense a generic 19 
medicine containing the same active ingredient, dosage, form and strength as the original medicine 20 
prescribed by the physicians. As generic medicines may differ with respect to name, shape, size, 21 
colour, taste and inert excipients, the act of substitution may therefore lead to confusion and 22 
misperception among patients, especially in elder patients. This may result in unintentionally 23 
decreased medication adherence, which translates in either not taking a medicine at all or taking 24 
double or triple doses of the same medicine. Generic substitution might also lead to concerns about 25 
the reliability of the medicine and insecurity about the intervention. This may have an unintentionally 26 
negative effect on medication adherence, as the patient may decide to not taking the substituted 27 
medicine [53-57].  Van Wijk et al., however, did not observe a relation between decreased medication 28 
adherence and generic substitution [48]. This difference might be explained by the fact that patients in 29 
the Netherlands are usually registered and serviced at a single pharmacy, which facilitates the 30 
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communication between the pharmacist and patient. This emphasises the importance of physicians’ 1 
and pharmacists’ role to inform patients about generic medicines and provide guidance in appropriate 2 
drug use [54;55;58]. Confusion due to different physical appearances of generic medicines might also 3 
be avoided if generic medicines manufacturers would be obliged to produce generic medicines with an 4 
similar appearance as originator medicines. This, however, may prove to be difficult as a product’s 5 
packaging and/or physical appearance that serves a branding function is protected by trade dress 6 
[59]. This is where pharmacists have to step up and play their role by informing and educating 7 
patients, as already described above. 8 
CASE STUDY 9 
An observational case study was carried out with data from the Netherlands to document the impact of 10 
generic entry on access to pharmacotherapy. Over the last years, the Dutch government and health 11 
insurers have implemented several policies to foster the use of generic medicines, which has resulted 12 
in widespread use of generic medicines. In addition, the introduction of the preference policy, which is 13 
a tendering system whereby health insurers only reimburse the lowest priced medicines, has resulted 14 
in very low prices. Looking at the evolution of total costs and total number of users, the selected active 15 
substances could be classified in three different groups. For some active substances, the total number 16 
of users increased after generic entry while total costs decreased at the same time (see Figure 1); for 17 
some active substances, the total number of users remained almost constant after generic entry while 18 
total costs decreased (see Figure 2); and for other active substances, the total number of users 19 
decreased after generic entry while total costs decreased (see Figure 3). 20 
[Insert Figure 1, 2 and 3 about here] 21 
In addition, an illustrative exercise was carried out to calculate the budget impact if no generic versions 22 
of the 14 active substances would have entered the market in the Netherlands. Assuming the number 23 
of counting DDD would have evolved in the same way as with generic entry, Table 1 shows the impact 24 
on the pharmaceutical budget if no generic versions of the 14 selected active substances would have 25 
entered the market. The numbers shown are the cumulative additional budget impacts for the 26 
respective active substance for all the years between generic entry and 2013 for the respective 27 
scenarios. For instance, if the cost/DDD of omeprazol would have remained at the level of 1 year 28 
before generic entry, this would have cost the Dutch government an additional €3.723bn between 29 
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2002 and 2014.  This illustrative exercise illustrates the importance of generic medicines to contain 1 
pharmaceutical expenditures while at the same time increasing access to pharmacotherapy. 2 
[Insert Table 1 about here] 3 
However, it is only one scenario to assume that the same rise in use would have taken place if the 4 
cost had remained high. As such, an additional illustrative exercise was carried out to calculate the 5 
impact of generic entry on the number of users. Assuming the costs would have evolved in the same 6 
way as with generic entry, Table 2 shows the impact on the number of users if no generic versions of 7 
the 14 selected active substances would have entered the market in the Netherlands. For instance, of 8 
the cost/user of omeprazole would have remained at the level of 1 year before generic entry, the total 9 
costs in 2013 would have only allowed to accommodate around 118.000 users instead of the 10 
1.040.000 at this moment.  These calculations show the increase in number of users that has been 11 
made possible by entrance of generic medicines at lower prices. 12 
[Insert Table2 about here] 13 
DISCUSSION 14 
Generic medicines have been a popular means for governments to contain pharmaceutical 15 
expenditures, as extensively demonstrated in the literature [6-9;12-17]. This paper has shown that 16 
generic medicines have more benefits than only in terms of generating cost-savings through reduced 17 
prices. Firstly, generic medicines improve access to pharmacotherapy. The reduced price of generic 18 
medicines improves the cost-effectiveness of existing pharmacotherapy, makes it cost-effective to 19 
manage previously untreated patients or leads to a more optimal treatment of some diseases [24-27]. 20 
For instance, our illustrative exercises for the case study showed that without entrance of generic 21 
medicines, the Dutch health care system would have spent substantially more on medicines to 22 
accommodate the same number of users or would only have been able to accommodate substantially 23 
less patients with the same budget. However, it can be assumed that the evolution of total costs would 24 
have differed if generic medicines would not have entered the market. The case study also 25 
demonstrated that the total number of users substantially increased after generic entry for certain 26 
active substances but not for all. There might be several reasons to explain this even or decreased 27 
use such as changes in medical guidelines (e.g. simvastatin and pravastatin are the first-line treatment 28 
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options in the Netherlands since a few years), changes in reimbursement conditions (e.g. tightening of 1 
reimbursement conditns for proton pump inhibitors) or the entrance of more effective alternatives,  2 
However, a shift of marketing strategies of originator companies, where originator companies try to 3 
switch the patient from the cheaper off-patent medicine to newer, more expensive medicines still 4 
under patent is a well-documented reason for a decreased use of some active substances after 5 
entrance of generic medicines [60]. Some originator companies even used denigration strategies to 6 
limit the use of generic medicines, which has already led to fines imposed by the authorities [61-63]. 7 
However, one must be careful that the reduced prices of generic medicines do not lead to overuse of 8 
certain medicines. Therefore, physicians continue to have an important responsibility to prescribe a 9 
medicine only if medically justified, even if they are cheap. 10 
Generic medicines have also an important impact on innovation. The entry of generic medicines and 11 
the resulting competition reduces the turn-over of originator companies on the respective product. As 12 
such, this is an incentive for originator companies to innovate, being either real or perceived, which 13 
can be achieved in a number of ways. The best way (for society) therefore is to channel more 14 
resources in research and development for new, clinically meaningful innovative products to keep the 15 
companies’ product portfolio competitive. Another, less risky strategy which is frequently used by 16 
originator companies is to prolong the lifetime of successful products by incremental innovations to 17 
extend the patent period (i.e. controlled-release formulations, single isomer drugs,  etc.) [30]. 18 
However, this might not be of significant added value from a societal perspective, as premium prices 19 
have to be paid for products with limited added value compared to the existing products. It is the 20 
difficult task of governments and legislators to find a balance between the length of patent protection 21 
to enable manufacturers to recoup their investments in R&D and savings by the entrance of generic 22 
medicines. Generic medicines also have another impact on innovation, as many generic medicines 23 
companies aim to innovate by concentrating on patients’ and pharmacists’ needs in their quest to get 24 
a competitive advantage over other pharmaceutical companies [21;31]. 25 
Lastly, generic medicines might also have a positive impact on medication adherence. The reduced 26 
prices of generic medicines might improve medication adherence, as high out-of-pocket costs for 27 
medicines are one of the best documented barriers to medication adherence [32]. However, the 28 
entrance of generic medicines and the associated act of generic substitution might also lead to 29 
confusion and misperception among patients, which might eventually result in unintentionally 30 
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decreased medication adherence. In Europe, several governments have implemented measures to 1 
encourage the prescribing of generic medicines. However, in most cases physicians remain free in 2 
their decision to prescribe a generic versus originator medicines. Nevertheless, generic substitution by 3 
the pharmacists is allowed in many European countries, although the physician can prevent generic 4 
substitution in most countries [10]. In case of substitution, this is where physicians and pharmacists 5 
have to take up their informative and educational role for patients to explain the concept of generic 6 
medicines and thereby prevent confusion and misperception. Generic medicines thus might have a 7 
potentially positive impact on medication adherence but only under the right circumstances.  8 
Over the last years, the introduction of new, innovative drug has declined and it will be interesting to 9 
monitor the impact on the generic medicines industry. In the US, prices of some generic medicines 10 
also increased over the last years, as recently observed, but there are no signs on this moment that 11 
the same phenomenon is happening in Europe [64]. However, these increased prices of generic 12 
medicines are likely caused by the fact that some companies went out of business in the respective 13 
markets due to the low profitability as results of the reduced prices. This reduced competition created 14 
monopolistic conditions for some molecules, which led to increased prices. 15 
Taking into account the many benefits of generic medicines, as illustrated before, governments must 16 
realize that continuously putting pressure on the prices of generic medicines and treating them solely 17 
as a cost-saving mechanism will serve only to stifle their capability to deliver continued benefits long-18 
term [21]. The business model of the generic medicines industry is based on the supply of high 19 
volume at low prices. As such, concentrating on the prices of generic medicines without appropriate 20 
measures to increase their volume jeopardizes the long-term sustainability of this industry [65]. This 21 
was also demonstrated in previous research, which showed that the extent to which price competition 22 
from generic medicines leads to price reductions is associated with their market share [66]. A viable 23 
and sustainable generic medicines market is thus needed to continue profiting from generic medicines’ 24 
benefits in the long-term. Governments must therefore implement a coherent set of policies on both 25 
the supply-side and the demand-side to sustain the development of a sustainable generic medicines 26 
market. 27 
 28 
 29 
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FIGURES 1 
 
 
  
 
Figure 1: Evolution of total costs and total number of users for five active substances of which the total number of 
users increased after generic entry while the total costs decreased. The vertical line indicates the time of generic 
entry. 
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Figure 2: Evolution of total costs and total number of users for five active substances of which the total number of 
users remained constant after generic entry while the total costs decreased. The vertical line indicates the time of 
generic entry. 
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Figure 3: Evolution of total costs and total number of users for five active substances of which the total number of 
users decreased after generic entry while the total costs decreased. The vertical line indicates the time of generic 
entry. 
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TABLES 1 
Active 
substance 
Year of 
generic entry 
Cumulative additional budget impact from year of generic entry until 2013 
Scenario 1: 
Cost/DDD of 
originator 1y before 
generic entry 
Scenario 2: 
Cost/DDD 
 -25% 
Scenario 3: 
Cost/DDD  
-50% 
Scenario 4: 
Cost/DDD 
originator 2013 
Omeprazol 2002 €3.723.211.200 €2.485.790.959 €1.248.370.718 €278.914.203 
Simvastatin 2003 €3.113.110.854 €2.169515.868 €1.225.920.882 €92.847.327 
Amlodipine 2004 €512.592.561 €323.948.636 €135.304.712 €-24.349.674 
Lisinopril 2002 €203.481.074 €114.016.890 €24.552.707 €-26.982.167 
Perindopril 2006 €248.644.918 €146.424.076 €44.203.234 €38.472.526 
      
Clopidogrel 2009 €171.295.644 €105.403.600 €39.511.556 €-55.096.848 
Ramipril 2004 €83.560.214 €50.247.347 €16.934.480 €-34.800.651 
Temozolomide 2010 €22.118.058 €11.812.928 €1.507.798 €12.980.117 
Alendronic acid 2005 €260.027.874 €154.482.802 €48.937.731 €23.532.389 
      
Esomeprazol 2010 €117.128.314 €37.499.26 €-42.129.778 €31.724.186 
Pantoprazol 2009 €628.212.327 €417.912.301 €207.612.275 €43.677.412 
Fluvastatin 2008 €13.06.634 €5.172.827 €-2.718.980 €-2.097.061 
Felodipine 2003 €10.784.844 €2.979.650 €-4.825.454 €14.032.246 
Quinapril 2004 €42.530.801 €21.471.360 €411.919 €-8.657.306 
Table 1: Additional budget impact in case of no generic entry. Four different scenarios are calculated in which the 2 
cost/DDD of the originator medicine remained at the level of 1 year before generic entry, decreased by 25%, 3 
decreased by 50% or decreased to the level of the cost/DDD of the originator medicine in 2013. The data shown 4 
in the table are the cumulative additional budget impact for the Dutch government from the year of generic entry 5 
until 2013 for the respective scenario. 6 
 7 
Active substance Number of users in 2013 
Number of users in 2013 
if price remained constant 
Additional users through 
entrance of generic 
medicines 
Omeprazol 1.039.096 117.847 921.249 
Simvastatin 1.071.042 124.585 946.457 
Amlodipine 447.908 88.164 359.744 
Lisinopril 227.301 62.446 164.855 
Perindopril 276.703 73.980 202.723 
 
   
Clopidogrel 127.923 15.171 112.752 
19 
 
Ramipril 57.346 12.999 44.347 
Temozolomide 1107 16 1091 
Alendronic acid 140.178 20.967 119.211 
 
   
Esomeprazol 243.995 119.162 124.833 
Pantoprazol 587.430 134.671 452.759 
Fluvastatin 21.327 6.475 14.852 
Felodipine 12.183 6.241 5.942 
Quinapril 28.473 11.266 17.207 
Table 2: Additional impact on number of users in case of no generic entry. Assuming that the total costs would 1 
have evolved as they actually did and that the average cost/user would have remained at the level of the year 2 
prior to generic entry, the number of possible users with the budget in 2013 are calculated. 3 
 4 
  5 
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